Our findings regarding the favorable effect of GLP-1RA on glycemic control, body weight, and total insulin dose are in line with the findings of another recent meta-analysis which reported results for liraglutide, exenatide, lixisenatide, and albiglutide and showed that addition of a GLP-1RA on top of insulin treatment decreased HbA1c by 0.21%, decreased body weight by 3.78 kg and decreased TID by 5.84 U/day while not increasing the risk of severe hypoglycemia [12]. Here, INS is linked to Hypoglycemia.